Evolent Health (NYSE:EVH – Free Report) had its target price cut by Canaccord Genuity Group from $45.00 to $44.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the technology company’s stock. A number of other equities analysts have also issued reports on the company. Oppenheimer assumed […]
Evolent Health (NYSE:EVH – Free Report) had its target price cut by Canaccord Genuity Group from $45.00 to $44.00 in a report published on Thursday morning, Benzinga reports. They currently have a buy rating on the technology company’s stock. Several other analysts have also commented on EVH. William Blair reiterated an outperform rating on shares […]
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]